A CONTROVERSIAL treatment for attention deficit hyperactivity disorder has been added to the Pharmaceutical Benefits Scheme, despite potential to cause suicidal thoughts and stunt growth. The move comes after a Therapeutic Goods Administration assessment of Strattera last year, which identified suicidal thoughts, agitation, weight loss, chest pain and swollen testicles as potential side effects of the drug.
- About
- Projects
- Library
- Bibliography of Bioethics
- Bioethics News
- For Students
- Contacts
- NBNPM
- Advanced Certificate Program
Papildomos nuorodos
